OBJECTIVES: The goal of this study was to investigate the frequency of GM1 antibodies and to assess whether exposure to Campylobacter jejuni was associated with a distinct clinical variant of Guillain-Barré Syndrome (GBS) or disease outcome in Rio Grande do Norte, Brazil. MATERIAL AND METHODS: Forty-one patients with a presumed diagnosis of GBS were enrolled and prospectively studied between June 1994 and November 1999. RESULTS: Anti-GM1 was present in 51.2% (n = 21) of patients. The presence of anti-GM1 was significantly associated with acute axonal motor neuropathy when compared to acute inflammatory demyelinating polyneuropathy (P = 0.01). Patients with anti-GM1 antibodies presented distal muscle involvement and fewer sensory deficits. Age, time to nadir and ventilatory assistance were not associated with anti-GM1 antibodies. Eight out of 21 patients (32%) presented with anti-C. jejuni antibodies. Clinical features were similar for patients with GBS with positive and negative C. jejuni antibodies. Anti-GM1 antibodies were associated with C. jejuni infection (P = 0.0005). Presence of anti-GM1 and C. jejuni antibodies did not indicate a worse prognosis. CONCLUSION: Patients with GBS and anti-GM1 antibodies had more distal muscle weakness, fewer sensory deficits, more axonal degeneration and C. jejuni infection, but these findings were not associated with a worse prognosis.
OBJECTIVES: The goal of this study was to investigate the frequency of GM1 antibodies and to assess whether exposure to Campylobacter jejuni was associated with a distinct clinical variant of Guillain-Barré Syndrome (GBS) or disease outcome in Rio Grande do Norte, Brazil. MATERIAL AND METHODS: Forty-one patients with a presumed diagnosis of GBS were enrolled and prospectively studied between June 1994 and November 1999. RESULTS: Anti-GM1 was present in 51.2% (n = 21) of patients. The presence of anti-GM1 was significantly associated with acute axonal motor neuropathy when compared to acute inflammatory demyelinating polyneuropathy (P = 0.01). Patients with anti-GM1 antibodies presented distal muscle involvement and fewer sensory deficits. Age, time to nadir and ventilatory assistance were not associated with anti-GM1 antibodies. Eight out of 21 patients (32%) presented with anti-C. jejuni antibodies. Clinical features were similar for patients with GBS with positive and negative C. jejuni antibodies. Anti-GM1 antibodies were associated with C. jejuniinfection (P = 0.0005). Presence of anti-GM1 and C. jejuni antibodies did not indicate a worse prognosis. CONCLUSION:Patients with GBS and anti-GM1 antibodies had more distal muscle weakness, fewer sensory deficits, more axonal degeneration and C. jejuniinfection, but these findings were not associated with a worse prognosis.
Authors: A Hiraga; M Mori; K Ogawara; S Kojima; T Kanesaka; S Misawa; T Hattori; S Kuwabara Journal: J Neurol Neurosurg Psychiatry Date: 2005-05 Impact factor: 10.154
Authors: María P Mahecha; Ernesto Ojeda; Daniel A Vega; Juan C Sarmiento-Monroy; Juan-Manuel Anaya Journal: Immunol Res Date: 2017-02 Impact factor: 2.829
Authors: Sonja E Leonhard; Cheng Yin Tan; Annemiek A van der Eijk; Ricardo R Reisin; Suzanne C Franken; Ruth Huizinga; Samuel Arends; Manou R Batstra; Selma M Bezerra Jeronimo; Judith Drenthen; Laura de Koning; Luciana Leon Cejas; Cintia Marchesoni; Wilson Marques; Nortina Shahrizaila; Dardo F Casas; Andrea Sotelo; Belen Tillard; Mario-Emilio Dourado; Bart C Jacobs Journal: J Peripher Nerv Syst Date: 2021-09-30 Impact factor: 5.188
Authors: E Scarcelli; R M Piatti; R Harakava; S Miyashiro; F R Campos; M C A Souza; M V Cardoso; S R Teixeira; M E Genovez Journal: Braz J Microbiol Date: 2009-12-01 Impact factor: 2.476